Direct Healthcare Professional Communication (DHPC) on Voxzogo® (vosoritide): change to administration syringe and needle leading to product administration in Units (U) instead of mL

The Federal Institute for Drugs and Medical Devices (BfArM) has released important information regarding the pharmacovigilance of Voxzogo® (vosoritide).

The latest update pertains to a change in the administration syringe and needle, resulting in product administration now measured in Units (U) instead of mL. This change is aimed at enhancing the precision and accuracy of dosage administration.

BfArM, being the authority responsible for drug safety in Germany, would like to ensure that this vital information reaches all healthcare professionals directly. 

Read more here:

https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/EN/RHB/2023/rhb-voxzogo.html?nn=968840

Subscribe to our newsletter Get the latest update Subscribe Now

Continue exploring

Latest News

Ready to simplify your journey?

Talk to our experts and get tailored solutions to help you stay compliant and move forward with confidence.

Request Free Consultation Submit RFI/RFP

No commitment required · 48h response time